Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences, a 10% owner and director of Xilio Therapeutics, converted 13.3 million Series B Warrants into Prefunded Warrants, increasing its beneficial ownership.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock for $125.23 per share, executed under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, exercised stock options and subsequently sold a portion of her shares as part of a pre-arranged trading plan.

Gilead Sciences' EVP of Corporate Affairs and General Counsel, Deborah H. Telman, exercised stock options and subsequently sold common stock totaling 53,646 shares under a pre-arranged trading plan.

Gilead Sciences CEO Daniel O'Day sold 10,000 shares of common stock on October 28, 2025, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences EVP Deborah Telman reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Gilead Sciences CFO Andrew D. Dickinson sold 2,500 shares of common stock for $118.08 per share, pursuant to a pre-arranged 10b5-1 trading plan.

Gilead Sciences Chief Commercial Officer Johanna Mercier sold 3,000 shares of common stock for $118.08 per share on October 15, 2025, under a pre-arranged trading plan.

Gilead Sciences, a 10% owner and director, acquired additional common stock and warrants in Assembly Biosciences through a private placement.

Gilead Sciences CEO Daniel O'Day sold a total of 10,000 shares of common stock on September 29, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences, Inc. SVP of Controllership, Erin Burkhart, was granted 8,890 restricted stock units with a four-year vesting schedule.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, sold 3,000 shares of common stock for $113.57 per share under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock for $113.57 per share under a pre-arranged trading plan.

Gilead Sciences CEO Daniel O'Day exercised restricted stock units and acquired common stock, with a portion sold to cover tax liabilities.

Gilead Sciences' Interim Corporate Controller and CAO, Diane E. Wilfong, reported the acquisition of common stock through RSU vesting and a subsequent sale for tax obligations.

Gilead Sciences' EVP Deborah H. Telman reported the vesting of restricted stock units and subsequent share sales for tax obligations.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, reported the acquisition of common stock through RSU vesting and a subsequent sale to cover tax liabilities.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported the vesting of restricted stock units and a subsequent sale of shares for tax withholding purposes.

Gilead Sciences CEO Daniel O'Day has reported a planned sale of 10,000 shares of common stock for $113.63 per share, scheduled for August 28, 2025, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, executed pre-planned transactions, exercising stock options and selling common stock on August 15, 2025, under a Rule 10b5-1 trading plan.

Gilead Sciences CFO Andrew D. Dickinson sold 2,500 shares of common stock for $118.53 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chairman and CEO, Daniel Patrick O'Day, sold 10,000 shares of common stock on July 28, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' EVP, Corporate Affairs & GC, Deborah H. Telman, reported the acquisition of common stock through restricted stock unit vesting and a related disposal for tax purposes.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, has filed a Form 4 disclosing a planned sale of 3,000 shares of common stock on July 15, 2025, under a pre-arranged 10b5-1 trading plan.

Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 2,500 shares of common stock for $111.03 per share under a Rule 10b5-1 trading plan.

Gilead Sciences Director Jeffrey Bluestone exercised non-qualified stock options and subsequently sold an equal number of common shares on July 14, 2025, under a Rule 10b5-1 trading plan.

Gilead Sciences' Chairman and CEO, Daniel Patrick O'Day, sold 10,000 shares of common stock for approximately $1.1 million through a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, has filed a Form 4 disclosing a future sale of 2,500 shares of common stock under a pre-arranged 10b5-1 trading plan.

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, sold 3,000 shares of common stock for $110.17 per share on June 16, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Diane E. Wilfong, Interim Corporate Controller and CAO of Gilead Sciences, Inc., reported the acquisition of common stock through the vesting of restricted stock units and a subsequent sale to cover tax obligations.